DPYSL2 and urinary bladder carcinoma: While aberrant expression of CRMP2 and nuclear phosphorylated CRMP2 were implicated in various malignancies, with increased expression in colorectal carcinoma [43] and bladder cancer [21], and decreased expression in breast cancer [19].